JP2024509276A - キナーゼ阻害剤の塩及び固体形態 - Google Patents

キナーゼ阻害剤の塩及び固体形態 Download PDF

Info

Publication number
JP2024509276A
JP2024509276A JP2023555320A JP2023555320A JP2024509276A JP 2024509276 A JP2024509276 A JP 2024509276A JP 2023555320 A JP2023555320 A JP 2023555320A JP 2023555320 A JP2023555320 A JP 2023555320A JP 2024509276 A JP2024509276 A JP 2024509276A
Authority
JP
Japan
Prior art keywords
salt
compound
ray powder
powder diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509276A5 (https=
Inventor
ヘインリッチ，ブライアン
リー，フイ
リー，クリストファー
メデンドープ，クレア・オーブリー
マッキーカーン，ローレン
バトラー，エリカ
キンキマ，ケイトリン
デイブ，ニミタ
ドン・シー，トゥアン
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2024509276A publication Critical patent/JP2024509276A/ja
Publication of JP2024509276A5 publication Critical patent/JP2024509276A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2023555320A 2021-03-10 2022-03-10 キナーゼ阻害剤の塩及び固体形態 Pending JP2024509276A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163159107P 2021-03-10 2021-03-10
US63/159,107 2021-03-10
US202163208641P 2021-06-09 2021-06-09
US63/208,641 2021-06-09
PCT/US2022/019776 WO2022192558A1 (en) 2021-03-10 2022-03-10 Salt and solid forms of a kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2024509276A true JP2024509276A (ja) 2024-02-29
JP2024509276A5 JP2024509276A5 (https=) 2025-03-14

Family

ID=81074313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555320A Pending JP2024509276A (ja) 2021-03-10 2022-03-10 キナーゼ阻害剤の塩及び固体形態

Country Status (11)

Country Link
US (1) US20240254130A1 (https=)
EP (1) EP4305036A1 (https=)
JP (1) JP2024509276A (https=)
KR (1) KR20240013720A (https=)
AU (1) AU2022234314A1 (https=)
BR (1) BR112023018246A2 (https=)
CA (1) CA3211477A1 (https=)
CR (1) CR20230479A (https=)
IL (1) IL305791A (https=)
MX (1) MX2023010606A (https=)
WO (1) WO2022192558A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
WO2024171143A1 (en) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200325141A1 (en) * 2019-04-12 2020-10-15 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200325141A1 (en) * 2019-04-12 2020-10-15 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005705945 *
第十六改正 日本薬局方, JPN6014035187, 2011, pages 64 - 68, ISSN: 0005705946 *

Also Published As

Publication number Publication date
US20240254130A1 (en) 2024-08-01
EP4305036A1 (en) 2024-01-17
BR112023018246A2 (pt) 2024-01-30
CA3211477A1 (en) 2022-09-15
AU2022234314A1 (en) 2023-09-28
MX2023010606A (es) 2023-10-19
KR20240013720A (ko) 2024-01-30
CR20230479A (es) 2024-03-08
WO2022192558A1 (en) 2022-09-15
IL305791A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
EP3856341B1 (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
AU2014254050B2 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US20250281492A1 (en) New crystalline forms of salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
JP2017039702A (ja) ロルラチニブ遊離塩基の結晶形態
US20230233557A1 (en) Formulations comprising heterocyclic protein kinase inhibitors
EP4359400B1 (en) Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer
JP2024509276A (ja) キナーゼ阻害剤の塩及び固体形態
CN107686477A (zh) 作为cdk4/6抑制剂的新型化合物及其应用
US9453011B2 (en) Crystal form of dabrafenib mesylate and preparation method thereof
EP3023421A1 (en) Crystalline forms of afatinib dimaleate
EP4353729A1 (en) Polymorph of imidazolidinone compound, preparation method therefor and use thereof
CN117794935A (zh) 激酶抑制剂的盐和固体形式
EP3111960B1 (en) Nuclear medicine diagnostic imaging agent
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
CN120383595A (zh) 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物
CN117043159A (zh) Kras突变型癌症的治疗
EA052616B1 (ru) Кристаллические формы производных хиназолина, их получение, композиции и применение
HK40072166B (zh) 杂环化合物及其制备方法和用途
HK40058236A (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
HK40058236B (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
CA3195794A1 (en) Dosing regimens for cyclin?dependent kinase 7 (cdk7) inhibitors
HK40058860B (en) Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6- yl)amino)cyclohexyl)propan-2-ol
HK40058860A (en) Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6- yl)amino)cyclohexyl)propan-2-ol
HK40015557A (en) Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260409